Entity Address, City or Town Entity Address, City or Town Entity Ex Transition Period Entity Ex Transition Period Paid-in-Kind Interest Issuance of PIK interest debt Schedule of Accrued Liabilities [Table Text Block] Schedule of Accrued Expenses Repurchase right lapse rate. Repurchase Right Lapse Rate Initial repurchase right lapse rate Change in control description Change in Control Description Change in control description. Domestic Tax Authority [Member] Domestic Defined contribution plan liabilities. Defined Contribution Plans Liabilities Defined contribution plan liability Issuance of common stock under ATM facility Stock Issued During Period, Value, New Issues Research and Development Expense, Policy [Policy Text Block] Research and Development Expenses and Accruals Long term debt maturities repayments of principal and interest remainder of fiscal year. Long Term Debt Maturities Repayments Of Principal And Interest Remainder Of Fiscal Year 2022 Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Dividend yield Cashless exercise of common stock warrants, shares Cashless Exercise Of Common Stock Warrants Cashless exercise of common stock warrants. Amendment Flag Amendment Flag Minimum percentage of qualified cash on principal amount prior to third performance milestone. Minimum Percentage of Qualified Cash on Principal Amount Prior to Third Performance Milestone Percentage of qualified cash prior to Third performance milestone Property and equipment purchases included in accounts payable and accrued expenses Capital Expenditures Incurred but Not yet Paid Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Common stock, shares authorized for issuance Subsequent Event Type [Domain] Drug product. Drug Products [Member] Drug Product Operating Lease, Right-of-Use Asset Operating lease right-of-use assets Defined contribution pan employer discretionary match number of shares settled. Defined Contribution Plan Employer Discretionary Match Number Of Shares Settled 401(k) matching contribution, shares Employer discretionary match number of shares settled 2019 equity incentive plan. Two Thousand Nineteen Equity Incentive Plan [Member] 2019 Equity Incentive Plan Document Quarterly Report Document Quarterly Report Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Table] Debt instrument prepayment fee percentage of outstanding principal amount. Debt Instrument Prepayment Fee Percentage Of Outstanding Principal Amount Debt instrument, prepayment fee percentage of outstanding principal amount Sales commission payable as a percentage of sale of gross sales price per share. Sales Commission Payable as a percentage of sale of Gross Sales Price per share Sales commission payable as a percentage of sale of gross sales price per share Lander warrants expire term. Lander Warrants Expire Term Warrants expire term Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: amount representing interest Earnings Per Share, Policy [Policy Text Block] Net Loss Per Share Statement [Table] Statement [Table] Operating Lease, Liability, Noncurrent Operating lease liabilities Operating lease liabilities, non-current Operating Lease, Payments Cash payments for operating lease costs Stock Issued During Period, Shares, Employee Stock Purchase Plans ESPP shares issued, shares Incremental common shares attributable to exercise of warrants. Incremental Common Shares Attributable To Exercise Of Warrants Shares of common stock included in calculation of basic weighted-average common shares Number of Operating Segments Number of operating segment Preferred Stock, Shares Outstanding Preferred stock, outstanding shares Preferred stock, shares outstanding Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Common Stock, Capital Shares Reserved for Future Issuance Common stock reserved for future issuance (in shares) Common stock reserved for issuance Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value Per Share, Unvested Ending Balance Weighted Average Grant Date Fair Value Per Share, Unvested Beginning Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value Per Share, Vested Income Tax Authority [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Options Outstanding, Options forfeited, expired or cancelled Options Outstanding, Options forfeited, expired or cancelled Share-based compensation arrangement by share-based payment award, equity instruments other than options, share vesting. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Share Vesting Share vesting Purchase of additional offering expenses. Purchase Of Additional Offering Expenses Purchase of additional offering expenses Lessee, Operating Leases [Text Block] Lease Commitments Share-Based Payment Arrangement, Option [Member] Stock Options Operating Lease, Weighted Average Remaining Lease Term Weighted-average remaining lease term (in years) Share based compensation arrangement by share based payment award, options and other than options, grants in period gross. Share Based Compensation Arrangement By Share Based Payment Award Options and Other than Options, Grants In Period Gross Number of awards, granted Liabilities and Equity Total liabilities and stockholders’ equity Revenue Interest Financing Liability Revenue Interest Financing Liability [Text Block] Revenue interest financing liability. Plan Name [Domain] Plan Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Income Statement [Abstract] Nonfinancial assets fair value disclosure. Nonfinancial Assets Fair Value Disclosure Non-financial assets fair value disclosure Nonfinancial Liabilities Fair Value Disclosure Non-financial liabilities fair value disclosure Nonfinancial Liabilities Fair Value Disclosure, Total Sale of Stock [Domain] Sale of Stock Proceeds from the Revenue Interest Financing Agreement Gross proceeds Gross Proceeds from Revenue Interest Financing Agreement Gross proceeds from revenue interest financing agreement. Liabilities, Current Total current liabilities Expected cash dividend yield rate. Expected Cash Dividend Yield Rate Expected cash dividend yield Stock Issued During Period, Value, Employee Stock Purchase Plan ESPP shares issued Common stock warrants. Common Stock Warrant [Member] Common stock warrants Fair Value, Recurring [Member] Fair Value, Recurring Interest Expense Interest expense Interest Expense, Total Income Tax, Policy [Policy Text Block] Income Taxes Agreement expiration term from date of first commercial sale. Agreement Expiration Term From Date Of First Commercial Sale Agreement expiration term from date of first commercial sale Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate Maximum percentage of eligible compensation contributed by participants Preferred Stock, Shares Authorized Preferred stock, authorized shares Preferred stock, shares authorized Additional warrant issued. Additional Warrant Issued Additional warrant issued Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Operating Lease, Weighted Average Discount Rate, Percent Weighted-average incremental borrowing rate Revenue Interest Financing Agreement [Member] Revenue Interest Financing Agreement Organization basis of presentation and summary of significant accounting policies. Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items] Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items] Variable Rate [Axis] Variable Rate Entity Small Business Entity Small Business Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Compensation Related Costs, Policy [Policy Text Block] Stock-Based Compensation Revenue Interest Financing Liability Revenue Interest Financing Liability [Policy Text Block] Revenue interest financing liability. Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased Remaining number of shares to be repurchased Investments [Domain] Payment for license amount. Payment For License Amount Cash consideration paid for license Payment in kind PIK interest rate. Payment in Kind PIK Interest Rate [Member] Payment In Kind PIK Interest Rate Area of Land Area for operating lease Assets, Current Total current assets Property, Plant and Equipment [Line Items] Property Plant And Equipment [Line Items] Increase (decrease) in accounts payable and accrued expenses related parties. Increase Decrease In Accounts Payable And Accrued Expenses Related Parties Related parties accounts payable and accrued expenses 2023 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Weighted-average shares of common stock outstanding, basic Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Basic, Total Interest bearing rate upon customary events. Interest Bearing Rate Upon Customary Events Interest bearing rate upon customary events Commitments and contingencies. Commitments And Contingencies [Table] Commitments And Contingencies [Table] City Area Code City Area Code Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value, Balance Long term debt noncurrent excluding unamortized debt discount. Long Term Debt Noncurrent Excluding Unamortized Debt Discount Long-term debt, non-current portion Prepaid expenses and other assets related parties current. Prepaid Expenses And Other Assets Related Parties Current Prepaid expenses and other current assets, related parties Options Outstanding, Options cancelled Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Upfront cash payment of investors additional funding amount available upon approval. Upfront Cash Payment of Investors Additional Funding Amount Available Upon Approval Upfront cash payment of investors additional funding amount available upon approval Share-Based Payment Arrangement [Abstract] Liabilities Total liabilities Document Period End Date Document Period End Date Stock issuance costs Payments of Stock Issuance Costs Loan agreement. Loan Agreement [Member] Loan Agreement Restricted Stock [Member] Restricted Stock Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum Annual increase to shares available for issuance percentage of outstanding common stock Long Term Debt Maturities Repayments Of Principal And Interest In Year Four Long term debt maturities repayments of principal and interest in year four. 2026 Construction In Progress Construction in Progress [Member] In Process Research and Development, Policy [Policy Text Block] In-Process Research and Development Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Estimated weighted-average fair value Lessee, Operating Lease, Renewal Term Operating lease, renewal term Share-Based Payment Arrangement, Tranche One [Member] First Anniversary Statistical Measurement [Axis] Statistical Measurement Accounts Payable, Related Parties, Current Accounts payable, related parties Investors right to receive royalties termination description Investors Right to Receive Royalties Termination Description Investors right to receive royalties termination description. Prepaid lease payments. Prepaid Lease Payments [Member] Prepaid Lease Payments Subsequent Event [Line Items] Component of Balance Sheet Disclosure. Component Of Balance Sheet Disclosure [Text Block] Balance Sheet Details Related Party [Axis] Related Party Percentage of investor share of royalty in net sales Percentage of investor share of royalty in net sales. Percentage of investor share of royalty in net sales Assets Total assets Tax cuts and jobs act, research and development expenditures amortization period. Research and development expenditures, amortization period Long-Term Debt, Excluding Current Maturities Long-term debt, net of discount Long-term Debt, Excluding Current Maturities, Total Net loss per share, diluted Earnings Per Share, Diluted Earnings Per Share, Diluted, Total Stock Repurchase Program Expiration Month and Year Stock Repurchase Program Expiration Month and Year Stock repurchase program expiration period Accrued expenses related parties current. Accrued Expenses Related Parties Current Accrued expenses, related parties Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Fiscal Period Focus Document Fiscal Period Focus Stock Repurchase Program, Period in Force Stock repurchase program, period in force Restricted cash Restricted Cash Restricted Cash, Total Summary of supplemental balance sheet information related to operating leases. Summary Of Supplemental Balance Sheet Information Related To Operating Leases Table [Text Block] Summary of Supplemental Balance Sheet Information Related to the Operating Leases Lender warrants exercisable shares of common stock. Lender Warrants Exercisable Shares Of Common Stock Warrants exercisable shares of common stock Deferred Offering Costs Offering costs Preferred stock, $0.0001 par value; authorized shares - 40,000,000 at March 31, 2023 and December 31, 2022; no shares issued and outstanding at March 31, 2023 and December 31, 2022 Preferred Stock, Value, Issued Preferred Stock, Value, Issued, Total Preferred Stock, Value, Issued, Beginning Balance Preferred Stock, Value, Issued, Ending Balance APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total Initial Investors NQ, Sagard, and Hercules Initial Investors NQ, Sagard, and Hercules [Member] Initial Investors NQ, Sagard, and Hercules. Investment Income, Interest Interest income Counterparty Name [Domain] Purchase obligation due in first twenty four months. Purchase Obligation Due In First Twenty Four Months Purchase obligation in the first 24-month period Total operating lease liabilities Operating Lease, Liability Total operating lease liabilities Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Impairment of Long-Lived Assets to be Disposed of Impairment losses Statement of Financial Position [Abstract] Securities Act File Number Entity File Number Scenario [Domain] Statement of Cash Flows [Abstract] Contract with Customer, Liability [Abstract] Balance Sheet Related Disclosures [Abstract] Minimum market capitalization amount. Minimum Market Capitalization Amount Minimum market capitalization amount Ending liability balance Revenue interest financing liability Revenue Interest Financing Liability Revenue interest financing liability. Outstanding warrants issued to purchase shares Class of Warrant or Right, Number of Securities Called by Warrants or Rights Warrants issued to purchase shares Geographical [Domain] Geographical Statistical Measurement [Domain] Statistical Measurement Statement of Stockholders' Equity [Abstract] Sale of Stock [Axis] Sale of Stock Revenue Interest Financing Agreement Upon Occurrence of Event of Default between April 1, 2025, and April 1, 2028 Revenue Interest Financing Agreement Upon Occurrence of Event of Default Between April One Two Thousand and Twenty Five and April One Two Thousand and Twenty Eight [Member] Revenue interest financing agreement upon occurrence of event between April one two thousand and twenty five and April one two thousand and twenty eight. Subsequent Events [Abstract] Additional investors funding commitment potential amount available upon approval. Additional Investors Funding Commitment Potential Amount Available Upon Approval Additional investors funding commitment potential amount available upon EE approval Takeda warrants. Takeda Warrants [Member] Takeda Warrant Takeda Warrants Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted-Average Remaining Contractual Term, Options exercisable as of March 31, 2022 Proceeds from Issuance of Common Stock Proceeds from issuance of shares Net proceeds from issuance of common stock Debt instrument, interest rate percentage. Debt Instrument, Interest Rate Percentage Debt instrument interest rate Long-Term Debt, Type [Axis] Long-term Debt, Type Grantee Status [Axis] Grantee Status ILLINOIS Buffalo Grove, Illinois Property, Plant and Equipment [Table Text Block] Schedule of Property, Plant and Equipment, Net Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentrations of Credit Risk Antidilutive Securities [Axis] Antidilutive Securities Related Party Transaction, Expenses from Transactions with Related Party Expense related to services Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Lessee, Lease, Description [Line Items] Lessee Lease Description [Line Items] Subsequent Events [Text Block] Subsequent Event Revenue Interest Financing Liability [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Additional investors funding commitment potential amount available upon achievement of sales milestone. Additional Investors Funding Commitment Potential Amount Available Upon Achievement Of Sales Milestone Additional investors funding commitment potential amount available upon achievement of sales milestone Weighted-average shares of common stock outstanding, diluted Weighted Average Number of Shares Outstanding, Diluted Weighted Average Number of Shares Outstanding, Diluted, Total Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Organization, Basis of Presentation and Summary of Significant Accounting Policies Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Unrecognized stock-based compensation expense Computer equipment and software Computer Equipment [Member] General and Administrative Expense [Member] General and Administrative Expense Organization basis of presentation and summary of significant accounting policies. Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Table] Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Table] Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Unrecognized stock-based compensation expense Current Fiscal Year End Date Current Fiscal Year End Date Investment Type [Axis] Depreciation Depreciation expense Depreciation, Total Schedule of Total Revenue Interest Financing Liability Schedule of Revenue Interest Financing Liability [Table Text Block] Schedule of revenue interest financing liability. Cash and cash equivalents and restricted cash - end of period Cash and cash equivalents and restricted cash - beginning of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Stock Repurchased During Period, Shares Repurchases of shares Other Assets, Noncurrent Other long-term assets Other Assets, Noncurrent, Total Entity Address, Address Line One Entity Address, Address Line One Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options Granted and ESPP Awards Long term debt maturities repayments of principal and interest, year one. Long Term Debt Maturities Repayments Of Principal And Interest Due Next Twelve Months 2023 NonCash settlement of defined contribution plan liability in common stock. Non Cash Settlement Of Defined Contribution Plan Liability In Common Stock Settlement of 401(k) liability in common stock Accrued Liabilities, Current [Abstract] Supplemental Cash Flow Information [Abstract] Supplemental disclosure of cash flow information Principal Owner [Member] Frazier Employee stock purchase plan. Employee Stock Purchase Plan [Member] Employee Stock Purchase Plan ESPP Plan Long term debt maturities repayments of principal and interest in year three. Long Term Debt Maturities Repayments Of Principal And Interest In Year Three 2025 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Weighted-Average Exercise Price, Options forfeited, expired or cancelled Weighted-Average Exercise Price, Options forfeited, expired or cancelled Vesting [Axis] Vesting Preferred Stock, Shares Issued Preferred stock, issued shares Preferred stock, shares issued Preferred Stock, Shares Issued, Total Balance Sheet Location [Domain] Balance Sheet Location Research and development expense related party. Research And Development Expense Related Party Research and development expenses, related party Other Accrued Liabilities, Current Accrued other Payments to Acquire Property, Plant, and Equipment Cash paid for property, plant and equipment Payments to Acquire Property, Plant, and Equipment, Total Increase (Decrease) in Interest Payable, Net Accrued interest Accounts payable and accrued expenses related parties current. Accounts Payable And Accrued Expenses Related Parties Current Outstanding accounts payable and accrued expenses Outstanding accounts payable and accrued expenses Common stock shares issued Issuance of common stock under ATM facility, shares Stock Issued During Period, Shares, New Issues General and administrative expense related party. General And Administrative Expense Related Party General and administrative expenses, related party Investors receipt description Investors Receipt Description Investors receipt description. Minimum percentage of qualified cash on principal amount following third performance milestone. Minimum Percentage of Qualified Cash on Principal Amount Following Third Performance Milestone Minimum percentage of qualified cash following third performance milestone Funding Commitment Prior To June Thirty Two Thousand Twenty Four [Member] Funding Commitment Prior To June Thirty Two Thousand Twenty Four [Member] Prior to June 30, 2024 Percentage of debt funded to be issued as warrants to purchase common stock. Percentage of Debt Funded to be Issued as Warrants to Purchase Common Stock Percentage of debt funded to be issued as warrants to purchase common stock Related party transaction shared operating expenses due to transactions with related party. Related Party Transaction Shared Operating Expenses Due To Transactions With Related Party Shared operating expenses NonCash settlement of employee stock purchase plan liability in common stock. Non Cash Settlement Of Employee Stock Purchase Plan Liability In Common Stock Settlement of ESPP liability in common stock Aggregate financing amount. Aggregate Financing Amount Aggregate financing amount Selling, General and Administrative Expenses, Policy [Policy Text Block] General and Administrative Expenses Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Weighted-Average Exercise Price, Options cancelled Operating Income (Loss) Loss from operations Number of warrants remaining exercisable. Number of warrants remaining exercisable Debt Instrument, Interest Rate, Stated Percentage Debt instrument, interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Number of shares issued Lessee, Operating Lease, Option to Extend Operating lease, option to extend description Related Party [Domain] Related Party Additional Paid in Capital, Common Stock Additional paid-in capital Additional Paid in Capital, Common Stock, Beginning Balance Additional Paid in Capital, Common Stock, Ending Balance Scenario [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Unamortized Debt Issuance Expense Debt issuance costs Office Space. Office Space Accrued Professional Fees, Current Accrued professional & consulting expenses Class of Warrant or Right [Domain] Class of Warrant or Right Entity Filer Category Entity Filer Category Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block] Summary of Unvested Shares Operating Expenses Total operating expenses Entity Current Reporting Status Entity Current Reporting Status Stock Issued During Period, Value, Restricted Stock Award, Gross Vesting of restricted shares Liabilities, lessee. Liabilities Lessee [Abstract] Liabilities: Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Aggregate Intrinsic Value, Options exercisable as of March 31, 2022 Prime Rate [Member] Prime Rate Liquidity and capital resources. Liquidity And Capital Resources Policy [Text Block] Liquidity and Capital Resources Share based compensation arrangement by share based payment award number of shares available for grant annual increase. Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Annual Increase Number of shares remain available for issuance, annual increase Class of warrant or right, expire term. Class of Warrant or Right Expire Term Warrants expire term Term loan. Term Loan [Member] Term Loan Amount utilized of equity financing Amount Utilized of equity financing Amount Utilized of equity financing. Long term debt maturities repayments of principal and interest in year two. Long Term Debt Maturities Repayments Of Principal And Interest In Year Two 2024 Stock issued during period shares cashless exercise of common stock warrants. Stock Issued During Period Shares Cashless Exercise of Common Stock Warrants Cashless exercise of common stock warrants, shares Total stockholders' (deficit) equity Stockholders' Equity Attributable to Parent Ending balance Beginning balance Base Rate [Member] Floor Rate Entity Tax Identification Number Entity Tax Identification Number Income Statement Location [Axis] Income Statement Location Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Number of Stock Units, Forfeited Number of Stock Units, Forfeited Common stock, $0.0001 par value; authorized shares - 400,000,000 at March 31, 2023 and December 31, 2022; issued shares - 43,602,984 and 41,723,308 at March 31, 2023 and December 31, 2022, respectively; outstanding shares - 43,571,140 and 41,468,871 at March 31, 2023 and December 31, 2022, respectively Common Stock, Value, Issued Common stock fair value Common Stock, Value, Issued, Total Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Ending Balance Retained Earnings (Accumulated Deficit) Accumulated deficit Retained Earnings (Accumulated Deficit), Total Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Ending Balance Tranche extension amendment fee Tranche extension amendment fee Tranche extension amendment fee Available equity financing amount Available Aggregate offering price through equity financing Available Aggregate offering price through equity financing. Equity Components [Axis] Equity Components Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Upfront cash payment of investors funding amount available upon approval. Upfront Cash Payment of Investors Funding Amount Available Upon Approval Upfront cash payment of investors funding amount available upon approval Leases [Abstract] Operating lease, rental area. Operating lease, rental area Operating lease, rentable square feet Accounts payable and accrued expenses (includes changes in related party amounts of $137 and $2,719, respectively) Increase (Decrease) in Accounts Payable and Accrued Liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total Entity Emerging Growth Company Entity Emerging Growth Company Related Party Transaction [Axis] Related Party Transaction Operating Expenses [Abstract] Operating expenses: Revenue Interest Financing Agreement Upon Occurrence of Event of Default Prior to April 1, 2025 Revenue Interest Financing Agreement Upon Occurrence of Event of Default prior to April One Two thousand and Twenty Five [Member] Revenue interest financing agreement upon occurrence of event of default prior to April one two thousand and twenty five. Interest Expense, Debt Interest expense Interest Expense, Debt, Total Agreement extends period for termination. Agreement Extends Period For Termination Agreement extends period for termination Common stock reserved for future issuances. Common Stock Reserved For Future Issuances Table Table [Text Block] Summary of Common Stock Reserved for Future Issuance Adjustments to Additional Paid in Capital, Warrant Issued Adjustments to additional paid-in-capital, warrants issued Partner Type [Axis] Partner Type Stock options and performance-based awards. Stock Options And Performance Based Awards [Member] Stock Options and Performance-Based Units Outstanding Revenue Interest Financing Agreement Upon Occurrence of a Change in Control Event Earlier of April 1, 2024 or FDA Approval If Occurrence Prior May 3, 2023 Revenue Interest Financing Agreement Upon Occurrence of a Change in Control Event Earlier of April One Two Thousand and Twenty Four or FDA Approval If Occurrence Prior to May Three Two Thousand and Twenty Three [Member] Revenue interest financing agreement upon occurrence of a change in control event earlier of April one two thousand and twenty four or FDA approval If occurrence is prior to May three two thousand and twenty three. Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected term (in years) Clinical manufacturing services. Clinical Manufacturing Services [Member] Clinical Manufacturing Services Share-based payment arrangement, employee and nonemployee. Share Based Payment Arrangement Employee And Nonemployee [Member] Employee and Nonemployee Director Non-dilutive financing amount. Non Dilutive Financing Amount Non-dilutive financing amount Document Transition Report Document Transition Report Investors funding amount. Investors Funding Amount Investors funding amount Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value Per Share, Granted Revenue Interest Financing Agreement Upon Occurrence of a Change in Control Event Earlier of April 1, 2024 or FDA approval If occurrence is Thereafter to May 3, 2023 Revenue Interest Financing Agreement Upon Occurrence of a Change in Control Event Earlier of April One Two Thousand and Twenty Four or FDA approval If occurrence is Thereafter to May Three Two Thousand and Twenty Three [Member] Revenue interest financing agreement upon occurrence of a change in control event earlier of April one two thousand and twenty four or FDA approval If occurrence is thereafter to May three two thousand and twenty three. Total other expense Nonoperating Income (Expense) Depreciation, Depletion and Amortization Depreciation and amortization Depreciation, Depletion and Amortization, Total Shares issued, price per share after deductions. Shares Issued Price Per Share After Deductions Purchase price per share after deducting underwriting discounts and commissions Sale of Stock, Price Per Share Common stock, price per share Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Interest expense with revenue interest finance liability Plus: interest expense Interest Expense Related To Revenue Interest Financing Liability Interest expense related to revenue interest financing liability Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Stock issued during period shares exercise of warrants. Stock Issued During Period Shares Exercise of Warrants Warrants exercised to purchase shares Issuance of common stock from exercise of warrants, shares Amortization of Debt Issuance Costs Amortization of debt discount Net Income (Loss) Net loss Net loss and comprehensive loss Term loans, aggregate principal amount tranches two. Term Loans Aggregate Principal Amount Tranches Two [Member] Term Loans, Aggregate Principal Amount Tranches Two Assets, lessee. Assets Lessee [Abstract] Assets: Operating Lease, Liability, Current Operating lease liabilities, current Less: operating lease liabilities, current Investors additional funding amount upon FDA approval of vonoprazan for treatment of erosive esophagitis Investor additional funding amount upon approval. Investor Additional Funding Amount Upon Approval Additional Paid-in Capital [Member] Additional Paid-in Capital Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative Schedule of Maturities of Long-Term Debt [Table Text Block] Schedule of Future Minimum Principal and Interest Payments Under Term Loan Follow-on Public Offering Follow On Public Offering [Member] Follow on public offering. Entity Registrant Name Entity Registrant Name Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Ending Balance Stock Repurchase Program, Number of Shares Authorized to be Repurchased Number of shares authorized to repurchase Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options Class of warrant or right, expiration date. Class of Warrant or Right Expiration Date Warrants expiration date Accrued interest. Accrued Interest Accrued interest Debt Instrument, Maturity Date Debt instrument, maturity date Lessee, Lease, Description [Table] Lessee Lease Description [Table] Share-Based Payment Arrangement, Noncash Expense Stock-based compensation Share-based Payment Arrangement, Noncash Expense, Total Property, Plant and Equipment, Net Property, plant and equipment, net Total property, plant and equipment, net Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Ending Balance Debt Instrument, Unamortized Discount Unamortized debt discount Debt Instrument, Unamortized Discount, Total Award Type [Domain] Award Type Statement [Line Items] Statement [Line Items] Stock option performance-based unit and restricted stock unit. Stock Option Performance-based Unit and Restricted Stock Unit [Member] Stock options, PSUs and RSUs Stock Options, PSUs and RSUs Outstanding Percentage of aggregate payments on investment amount to investors on net sales Percentage Of Aggregate Payments On Investment Amount To Investors On Net Sales Percentage of aggregate payments on investment amount to investors on net sales. Operating Lease, Expense Operating leases, rent expense Title of 12(b) Security Title of 12(b) Security Revenue interest financing liability Revenue Interest Financing Liability Noncurrent Revenue interest financing liability noncurrent. Common Stock [Member] Common Stock Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities Hercules Loan Agreement Hercules Loan Agreement [Member] Hercules loan agreement. Equity Component [Domain] Equity Component Fair Value Measurement, Policy [Policy Text Block] Fair Value Measurements Computer equipment and software. Computer Equipment And Software [Member] Computer Equipment and Related Software Term loans, aggregate principal amount tranches three. Term Loans Aggregate Principal Amount Tranches Three [Member] Term Loans, Aggregate Principal Amount Tranches Three Entity Address, State or Province Entity Address, State or Province Geographical [Axis] Geographical Debt instrument final payment fee percentage. Debt Instrument Final Payment Fee Percentage Debt instrument, final payment fee percentage Fair value of warrant liabilities Initial fair value of warrants Fair value of warrants Net decrease in cash and cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Document Type Document Type Interest Paid, Excluding Capitalized Interest, Operating Activities Interest paid Entity Shell Company Entity Shell Company Share-Based Payment Arrangement, Expense Stock-based compensation expense Stock-based compensation cost Financial assets fair value disclosure. Financial Assets Fair Value Disclosure Financial assets fair value disclosure Term loans, aggregate principal amount tranches four. Term Loans Aggregate Principal Amount Tranches Four [Member] Term Loans, Aggregate Principal Amount Tranches Four Operating right-of-use assets and lease liabilities Increase (decrease) in operating right of use asset and lease liabilities. Increase Decrease In Operating Right Of Use Asset And Lease Liabilities Security Exchange Name Security Exchange Name Revenue Interest Financing Agreement Funding upon Achievement of Sales Milestone at any Time Prior to June 30, 2024 Revenue Interest Financing Agreement Funding Upon Achievement of Sales Milestone At Any Time prior To June Thirty Two Thousand and Twenty Four [Member] Revenue ​interest​ financing​ agreement​ funding upon achievement of sales milestone at any time prior to June thirty two thousand and twenty four. Maximum amount payable in sales milestones upon the achievement of specified levels of product sales. Maximum Amount Payable In Sales Milestones Upon Achievement Of Specified Levels Of Product Sales Maximum amount payable in sales milestones upon achievement of specified levels of product sales Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Debt instrument final payment fee. Debt Instrument Final Payment Fee Debt instrument, final payment fee Debt instrument, final payment fee or end of term charge Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Unrecognized stock-based compensation expense, weighted-average period for recognition Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted-Average Remaining Contractual Term Debt Instrument, Interest Rate, Effective Percentage Debt instrument, interest rate percentage Long term debt and interest. Long Term Debt And Interest Total principal and interest payments Default obligation description Default Obligation Description Default obligation description. Commitments and Contingencies Disclosure [Abstract] Interest Payable, Current Accrued interest Restricted Stock Units (RSUs) [Member] Restricted Stock Units (RSUs) Lessee, Operating Lease, Liability, Maturity [Table Text Block] Summary of Future Minimum Lease Payments Under Operating Leases Percentage of aggregate payment on investment amount to investors Percentage Of Aggregate Payments On Investment Amount To Investors Percentage of aggregate payments on investment amount to investors. Share-Based Payment Arrangement, Option, Activity [Table Text Block] Summary of Stock Option Activity New Accounting Pronouncements, Policy [Policy Text Block] Recently Adopted and Issued Accounting Pronouncements Common Stock, Shares, Outstanding Ending balance, shares Beginning balance, shares Common stock, outstanding shares Over-Allotment Option [Member] Underwritten Public Offering Debt Disclosure [Text Block] Debt Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities Commitments and Contingencies Commitments and contingencies (Note 4) Takeda pharmaceutical company limited. Takeda Pharmaceutical Company Limited [Member] Takeda Common Stock, Shares, Issued Common stock, issued shares Common stock, shares issued Common Stock, Shares, Issued, Total Revenue Interest Financing Agreement Percentage on Investment Amount On December December 31, 2028 Revenue Interest Financing Agreement Percentage on Investment Amount On December Thirty One Two Thousand And Twenty Eight [Member] Revenue interest financing agreement percentage on investment amount on December thirty one two thousand and twenty eight. Lender warrants. Lender Warrants [Member] Lender Warrants Variable Rate [Domain] Variable Rate Minimum [Member] Minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Description Equity plan, description Warrants expiration date. Warrants Expiration Date Warrants expiration date Debt instrument additional borrowing capacity amount. Debt Instrument Additional Borrowing Capacity Amount Debt instrument, additional borrowing capacity amount Grantee Status [Domain] Grantee Status Payment for facility charge. Payment for Facility Charge Payment for facility charge Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted-Average Exercise Price, Options exercisable as of March 31, 2022 Accrued expenses (including related party amounts of $2,608 and $2,499, respectively) Accrued Liabilities, Current Total accrued expenses Debt Instrument [Axis] Debt Instrument Stockholders' Equity Attributable to Parent [Abstract] Stockholders’ equity: Treasury Stock [Member] Treasury Stock Takeda license agreement. Takeda License Agreement [Member] Takeda License Takeda License Agreement Counterparty Name [Axis] Entity Address, Address Line Two Entity Address, Address Line Two Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value Per Share, Forfeited Award Type [Axis] Award Type Other Noncash Income (Expense), Total Other Noncash Income (Expense) Other Subsequent Event [Member] Subsequent Event Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Unrecognized stock-based compensation expense Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total Share based compensation arrangements by share based payment award options exercises and shares vested in period weighted average exercise price. Share Based Compensation Arrangements By Share Based Payment Award Options Exercises And Shares Vested In Period Weighted Average Exercise Price Weighted-Average Exercise Price, Options exercised and shares vested License agreement description. License Agreement Description License agreement description Related Party Transaction [Domain] Related Party Transaction Hercules and SVB term loan. Hercules and SVB Term Loan [Member] Hercules and SVB Term Loan Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Impairment of Long-Lived Assets Other income (expense) Other Nonoperating Income (Expense) Other Nonoperating Income (Expense), Total Increase decrease in clinical accrued trial expenses. Increase Decrease In Clinical Accrued Trial Expenses Accrued clinical trial expenses Long-Term Debt, Current Maturities Current portion of long-term debt Long-term debt, current portion Long-term Debt, Current Maturities, Total Nonoperating Income (Expense) [Abstract] Other income (expense): Revenue Interest Financing Agreement Upon Occurrence of Event of Default after April 1, 2028 Revenue Interest Financing Agreement Upon Occurrence of Event of Default After April One Two Thousand and Twenty Eight [Member] Revenue interest financing agreement upon occurrence of event of default after April one two thousand and twenty eight. Research and development (includes related party amounts of $175 and $1,430, respectively) Research and Development Expense Research and Development Expense, Total Lessee, Operating Lease, Liability, to be Paid Total minimum lease payments Lessee, Operating Lease, Term of Contract Operating lease term NEW JERSEY Florham Park, New Jersey Open Market Sale Agreement with Jefferies LLC. Open Market Sale Agreement With Jefferies L L C [Member] Open Market Sale Agreement with Jefferies LLC Entity Central Index Key Entity Central Index Key Food and drug administration. Food and Drug Administration [Member] FDA Lessee, Operating Lease, Existence of Option to Terminate [true false] Lessee, operating lease, existence of option to terminate Cars [Member]. Cars Leases Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract] Assumptions: Aggregate offering price through equity financing. Aggregate offering price through equity financing Aggregate offering price through equity financing Lessee operating lease number of option to extend. Lessee Operating Lease Number Of Option To Extend Operating lease number of option to extend Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Less: accumulated depreciation and amortization Property, Plant and Equipment [Table] Schedule Of Property Plant And Equipment [Table] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Measurement Frequency [Axis] Measurement Frequency Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Number of shares available for issuance Funds received from initial closing Funds Received from Initial Closing Funds received from initial closing. Share-Based Payment Arrangement [Text Block] Stockholders' Equity Term loans, aggregate principal amount tranches one. Term Loans Aggregate Principal Amount Tranches One [Member] Term Loans, Aggregate Principal Amount Tranches One Subsequent Event [Table] General and administrative (includes related party amounts of $3 and $0, respectively) General and Administrative Expense General and Administrative Expense, Total Organization, Consolidation and Presentation of Financial Statements [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted-Average Exercise Price, Ending Balance Weighted-Average Exercise Price, Beginning Balance Amendment to Loan Agreement Amendment to Loan Agreement [Member] Amendment to loan agreement. Research and Development Expense [Member] Research and Development Expense Fair Value, Nonrecurring [Member] Fair Value, Nonrecurring Forecast [Member] Forecast Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Stock repurchase program, number of shares right lapse. Stock Repurchase Program Number Of Shares Right Lapse Stock repurchase program, number of shares right lapse Retained Earnings [Member] Accumulated Deficit Amendment to Warrants Amendment to Warrants [Member] Amendment to warrants. Revenue Interest Financing Agreement Percentage On Investment Amount by December 31, 2037 Revenue Interest Financing Agreement Percentage On Investment Amount On December Thirty One Two Thousand And Thirty Seven [Member] Revenue interest financing agreement percentage on investment amount On December thirty one two thousand and thirty seven. Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Adjustments to additional paid in capital conversion of warrant liability into equity. Adjustments To Additional Paid In Capital Conversion Of Warrant Liability Into Equity Conversion of Lender Warrants into equity Conversion of Lender Warrants into equity Treasury Stock, Common, Shares Treasury stock, shares Property, Plant and Equipment, Gross Property, plant and equipment, gross Property, Plant and Equipment, Gross, Total Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Ending Balance Entity Interactive Data Current Entity Interactive Data Current Percentage of gross sales price per share sold. Percentage Of Gross Sales Price Per Share Sold Percentage of gross sales price per share sold Commercial supply agreements. Commercial Supply Agreements [Member] Commercial Supply Agreement Related Party Transactions Disclosure [Text Block] Related Party Transactions Less payment-in-kind and final payment fee Debt instrument interest and final payment fee. Debt Instrument Interest And Final Payment Fee Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Supplemental disclosure of noncash investing and financing activities Payments for Repurchase of Warrants Aggregate repurchase price of warrants Related Party Transactions [Abstract] Net proceeds after deducting underwriters commission. Net Proceeds After Deducting Underwriters Commission Net proceeds after deducting underwriters commission 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Treasury stock - 19 shares at March 31, 2023 and December 31, 2022, respectively Treasury stock - 19 shares at March 31, 2023 and December 31, 2022, respectively Treasury Stock, Common, Value Common Stock in Treasury - 19 and 1 at March 31, 2022 and December 31, 2021, respectively Founders. Founders [Member] Founders Leasehold Improvements [Member] Leasehold Improvements Share based compensation arrangement by share based payment award stock options exercised and shares vested. Share Based Compensation Arrangement By Share Based Payment Award Stock Options Exercised And Shares Vested Options Outstanding, Options exercised and shares vested Proceeds from Issuance Initial Public Offering Proceeds from Initial Public Offering (IPO) Local Phone Number Local Phone Number Frazier Life Sciences IX, limited partner member. Frazier Life Sciences I X Limited Partner [Member] Frazier Purchase commitment, expense. Purchase Commitment Expense Expenses incurred related to purchase commitments Repurchase right lapse shares. Repurchase Right Lapse Shares Repurchase right lapse each month after first anniversary, shares Revenue Interest Financing Agreement Upon Occurrence of a Change in Control Event Earlier of April 1, 2024 or FDA Approval If Occurrence Prior May 3, 2023 Revenue Interest Financing Agreement Upon Occurrence of a Change in Control Event Earlier of April One Two Thousand and Twenty Four or FDA Approval [Member] Revenue interest financing agreement upon occurrence of a Change in control event earlier of April one two thousand and twenty four or FDA Approval. Debt Disclosure [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Options Outstanding, Options exercisable as of March 31, 2022 Net proceeds Net Proceeds From Revenue Interest Financing Transaction Net proceeds from revenue interest financing transaction. IPO [Member] IPO Lessor, Leases [Policy Text Block] Leases Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Stock options, granted Options Outstanding, Options granted Other Liabilities, Noncurrent Other long-term liabilities Other Liabilities, Noncurrent, Total Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Schedule of Reconciliation of Liabilities Measured at Fair Value Debt Instrument, Payment Terms Debt instrument, description Income Statement Location [Domain] Income Statement Location Additional percentage to be paid with obligated payment on investment amount Additional Percentage to be Paid with Obligated Payment On Investment Amount Additional percentage to be paid with obligated payment on investment amount. Property, Plant and Equipment [Abstract] Balance at March 31, 2023 Balance at December 31, 2022 Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Long-Term Debt Total debt, net of debt discount Investors additional funding amount upon achievement of sales milestone. Investors Additional Funding Amount Upon Achievement of Sales Milestone Investors additional funding amount upon achievement of sales milestone Proceeds from issuance initial public offering gross. Proceeds From Issuance Initial Public Offering Gross Proceeds from issuance initial public offering gross Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Prepaid Expense and Other Assets, Total Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Commitments and contingencies. Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Options Outstanding, Ending Balance Options Outstanding, Beginning Balance Debt Instrument, Name [Domain] Debt Instrument, Name Temporary services agreement. Temporary Services Agreement [Member] Temporary Services Agreement Document Fiscal Year Focus Document Fiscal Year Focus Repayments of Debt Final payment of debt Class of Warrant or Right [Axis] Class of Warrant or Right Purchase Obligation Minimum purchase obligation Purchase Obligation, Total Employees. Employees [Member] Employees 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two PCI Pharma Services. P C I Pharma Services [Member] PCI Pharma Services Vesting [Domain] Vesting Net loss per share, basic Earnings Per Share, Basic Earnings Per Share, Basic, Total Less: transaction costs Transaction costs Payment of Transaction Costs Payment of transaction costs. Assets [Abstract] Assets Schedule of Long-Term Debt Instruments [Table Text Block] Schedule of Total Debt Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Shares Issued, Price Per Share Public offering price per share Debt Instrument, Face Amount Aggregate amount of debt instrument Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset Term loan first advance. Term Loan First Advance [Member] Term Loan First Advance Liabilities and Equity [Abstract] Liabilities and Stockholders’ Equity Accrued Employee Benefits, Current Accrued compensation expenses Accrued interest on revenue interest financing liability Accrued Interest On Revenue Interest Financing Liability Accrued interest on revenue interest financing liability. Property, Plant and Equipment, Policy [Policy Text Block] Property, Plant, and Equipment, Net Antidilutive Securities, Name [Domain] Antidilutive Securities, Name Income Tax Authority [Axis] Term loan advance. Term Loan Advance [Member] Term Loan Advance Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Revenue Interest Financing Agreement, Funding Commitment On or Before March 31, 2024 Revenue Interest Financing Agreement Funding Commitment On Or Before March Thirty One Two Thousand And Twenty Four [Member] Revenue interest financing agreement funding commitment on or before March thirty one two thousand and twenty four. Assets, Current [Abstract] Current assets: Class of Warrant or Right, Exercise Price of Warrants or Rights Warrants exercise price Stock Repurchase Program Expiration Date Stock repurchase program expiration date Unvested shares. Unvested Shares [Member] Unvested Shares SVB term loan. Silicon Valley Bank Term Loan [Member] SVB Term Loan Defined Contribution Plan, Employer Discretionary Contribution Amount 401(k) matching contribution Measurement Frequency [Domain] Measurement Frequency Investors funding commitment potential amount available upon achievement of sales milestone Investors Funding Commitment Potential Amount Available Upon Achievement of Sales Milestone Investors funding commitment potential amount available upon achievement of sales milestone. Two thousand nineteen incentive award plan. Two Thousand Nineteen Incentive Award Plan [Member] 2019 Incentive Award Plan 2019 Incentive Award Plan Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Related Party Transaction [Line Items] Related Party Transaction [Line Items] Term Loans Aggregate Principal Amount Tranches Three And Four Term Loans Aggregate Principal Amount Tranches Three and Four [Member] Term loans aggregate principal amount tranches three and four. Property, Plant and Equipment, Disposals Disposal of property, plant or equipment Lessee, Operating Lease, Remaining Lease Term Operating leases, remaining lease terms Cover [Abstract] Stock Option Performance Based Awards Outstanding Stock Option Performance Based Unit [Member] Stock Option Performance Based Unit. Number of Stock Units, Vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Number of Stock Units, Vested Liabilities, Current [Abstract] Current liabilities: Maximum [Member] Maximum Defined Contribution Plan, Employer Matching Contribution, Percent of Match Defined contribution plan, employer matching contribution, percentage Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Summary of Stock-Based Compensation Expense Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Furniture and Fixtures [Member] Furniture and Fixtures Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Issuance of common stock from exercise of stock options, shares Use of Estimates, Policy [Policy Text Block] Use of Estimates Stock Issued During Period, Shares, Restricted Stock Award, Gross Vesting of restricted shares, shares Debt Instrument, Basis Spread on Variable Rate Debt instrument, basis spread on variable rate Shares aggregate repurchase price. Shares Aggregate Repurchase Price Shares aggregate repurchase price Stock Issued During Period, Value, Stock Options Exercised Issuance of common stock from exercise of stock options Commercial Supply Agreement and Temporary Services Agreement. Commercial Supply Agreement and Temporary Services Agreement [Member] Commercial Supply and Temporary Services Agreement Segment Reporting, Policy [Policy Text Block] Segment Reporting Passenger Vehicles. Passenger Vehicles Property, Plant and Equipment, Useful Life Property and equipment, useful life Covenant extension amendment fee Covenant extension amendment fee Covenant extension amendment fee. Defined Contribution Plan, Cost Defined contribution plan employer contribution liabilities expense Foreign Tax Authority [Member] Foreign Partner Type of Partners' Capital Account, Name [Domain] Partner Type of Partners' Capital Account, Name Long-term debt outstanding Total term loan borrowings Term loans aggregate principal amount Aggregate principal amount Common Stock, Shares Authorized Common stock, authorized shares Common stock, authorized shares Trading Symbol Trading Symbol Title of Individual [Domain] Title of Individual Subsequent Event Type [Axis] Performance Shares [Member] Performance-Based Stock Units (PSU) Share based compensation arrangement by share based payment award, options and other than options forfeitures and expirations in period. Share Based Compensation Arrangement By Share Based Payment Award, Options and Other Than Options Forfeitures and Expirations in Period Number of awards, cancelled or forfeited Initial investors funding amount available upon approval. Initial Investors Funding Amount Available Upon Approval Initial investors funding amount available upon approval Balance Sheet Location [Axis] Balance Sheet Location Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk free interest rate Revenue Interest Financing Agreement Funding upon FDA Approval at any Time Prior to December 31, 2022 Revenue Interest Financing Agreement Funding Upon FDA Approval At Any Time prior To December Thirty One Two Thousand and Twenty Two [Member] Revenue ​interest​ financing​ agreement​ funding upon FDA approval at any time prior to December thirty one two thousand and twenty two. Accounts payable (including related party amounts of $78 and $35, respectively) Accounts Payable, Current Accounts Payable, Current, Total Schedule of Nonvested Performance-Based Units Activity [Table Text Block] Summary of PSU Activity Under the 2019 Incentive Award Plan Accrued research and development expenses. Accrued Research And Development Expenses Accrued research and development expenses Plan Name [Axis] Plan Name At-the-market offering program. A T M Offering Program [Member] At-the-Market Offering Program Schedule of Related Party Transactions, by Related Party [Table] Schedule Of Related Party Transactions By Related Party [Table] Title of Individual [Axis] Title of Individual Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset Common Stock, Par or Stated Value Per Share Common stock, par value Funding Commitment On Or Before March Thirty One Two Thousand and twenty Four. Funding Commitment On Or Before March Thirty One Two Thousand and twenty Four [Member] On or Before March 31, 2024 Comprehensive Income, Policy [Policy Text Block] Comprehensive Loss Debt instrument facility charge percentage. Debt Instrument Facility Charge Percentage Debt instrument, facility charge percentage Potential additional investor funding amount Potential Additional Investor Funding Amount Potential additional investor funding amount. Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Stock awards, granted Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted-Average Exercise Price, Options granted Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Additional number of shares available for issuance Debt Instrument [Line Items] Debt Instrument [Line Items] Long-Term Debt, Type [Domain] Long-term Debt, Type Unvested shares excluded from computation of weighted average earnings per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Weighted-average unvested shares Funding Commitment Prior To December Thirty One Tow Thousand Twenty Two. Funding Commitment Prior To December Thirty One Two Thousand Twenty Two [member] Prior to December 31, 2022 Organization and basis of presentation. Organization and Basis of Presentation [Policy Text Block] Organization and Basis of Presentation Increase (Decrease) in Other Noncurrent Assets Other long-term assets